Illimis Therapeutics
ID: 17840783Illimis Therapeutics specializes in developing novel biologics based on its proprietary chimeric fusion protein platform. The platform aims to address neurodegenerative diseases such as Alzheimer's by utilizing TAM receptor-mediated phagocytosis, which reduces neuroinflammation
1
Funding Rounds
$42.0m
Money raised
Recent Funding Rounds
Overview
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
| Name | Phone | Social networks | |
|---|---|---|---|
| Sa****** Pa** | - | - | - |
| Wo**** Ch*** | - | - | - |
| Ch****** Ki* | - | - | - |
Funding series
Funding Series Analysis
The company Illimis Therapeutics has raised a total of $42m in funding over 1 rounds.
Key Insights:
- Illimis Therapeutics July 2025 Series B Funding Round: $42m